UPDATE: BMO Capital Downgrades Gilead Sciences (GILD) to Market Perform

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. MA
9. FND
10. DASH

Go back to UPDATE: BMO Capital Downgrades Gilead Sciences (GILD) to Market Perform

Gilead Sciences (GILD) Has an 80% Chance of Trading Higher on this Catalyst - Morgan Stanley

February 24, 2022 9:04 AM EST

Morgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $69.00 price target on Gilead Sciences (NASDAQ: GILD) seeing an 80% chance that shares move higher when Trodelvy HR+/HER2- mBC data is reported in March. TROPiCS-02 is an ongoing Phase III, open-label, randomized, multicenter study of sacituzumab govitecan (Trodelvy) versus physicians choice (TPC) in patients with HR+/HER2- metastatic breast cancer (MBC) who have... More

Gilead Sciences (GILD) PT Raised to $54 at UBS

February 24, 2022 4:24 AM EST

UBS analyst Colin Bristow raised the price target on Gilead Sciences (NASDAQ: GILD) to $54.00 (from $52.00) while maintaining a Buy rating.... More